Metropolitan Life Insurance Company (MetLife)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-845	Closed	-$292K	–	286
2024 Q1	$292K	Sell	845 -7	-0.8%	-$2.3K	0.01%	595
2023 Q4	$275K	Sell	852 -13	-2%	-$4.08K	0.01%	601
2023 Q3	$310K	Sell	865 -66	-7%	-$25.5K	0.02%	544
2023 Q2	$353K	Sell	931 -33	-3%	-$13.4K	0.02%	514
2023 Q1	$462K	Sell	964 -282	-23%	-$132K	0.02%	476
2022 Q4	$524K	Sell	1,246 -7	-0.6%	-$2.83K	0.02%	483
2022 Q3	$523K	Sell	1,253 -27	-2%	-$13.5K	0.02%	477
2022 Q2	$634K	Sell	1,280 -28	-2%	-$14.6K	0.03%	463
2022 Q1	$737K	Sell	1,308 -1,130	-46%	-$681K	0.03%	481
2021 Q4	$1.84M	Sell	2,438 -39	-2%	-$29.2K	0.03%	583
2021 Q3	$1.85M	Sell	2,477 -91	-4%	-$68.2K	0.03%	546
2021 Q2	$1.65M	Sell	2,568 -33	-1%	-$20.1K	0.02%	641
2021 Q1	$1.49M	Sell	2,601 -127	-5%	-$75.2K	0.02%	700
2020 Q4	$1.59M	Sell	2,728 -140	-5%	-$79.7K	0.02%	592
2020 Q3	$1.48M	Sell	2,868 -127	-4%	-$64.3K	0.03%	540
2020 Q2	$1.35M	Sell	2,995 -2,751	-48%	-$1.21M	0.02%	569
2020 Q1	$2.01M	Sell	5,746 -312	-5%	-$115K	0.04%	379
2019 Q4	$2.24M	Buy	6,058 +65	+1%	+$22.9K	0.04%	482
2019 Q3	$1.99M	Buy	5,993 +238	+4%	+$77.6K	0.03%	509
2019 Q2	$1.8M	Sell	5,755 -26	-0.4%	-$7.79K	0.03%	578
2019 Q1	$1.77M	Sell	5,781 -10	-0.2%	-$2.7K	0.03%	551
2018 Q4	$1.34M	Buy	5,791 +45	+0.8%	+$12.1K	0.03%	636
2018 Q3	$1.8M	Sell	5,746 -121	-2%	-$37.6K	0.03%	588
2018 Q2	$1.69M	Buy	5,867 +11	+0.2%	+$3.04K	0.03%	611
2018 Q1	$1.46M	Buy	5,856 +42	+0.7%	+$10.7K	0.02%	712
2017 Q4	$1.39M	Sell	5,814 -13,135	-69%	-$3.18M	0.02%	747
2017 Q3	$4.21M	Sell	18,949 -649	-3%	-$146K	0.03%	674
2017 Q2	$4.43M	Buy	19,598 +222	+1%	+$48.4K	0.03%	651
2017 Q1	$3.86M	Sell	19,376 -19	-0.1%	-$3.66K	0.03%	719
2016 Q4	$3.54M	Buy	19,395 +18	+0.1%	+$3.07K	0.03%	748
2016 Q3	$3.17M	Sell	19,377 -227	-1%	-$34.5K	0.02%	768
2016 Q2	$2.8M	Buy	19,604 +717	+4%	+$102K	0.02%	799
2016 Q1	$2.58M	Buy	18,887 +578	+3%	+$75.9K	0.02%	813
2015 Q4	$2.54M	Buy	18,309 +172	+0.9%	+$23.8K	0.02%	805
2015 Q3	$2.44M	Sell	18,137 -164	-0.9%	-$23.6K	0.02%	831
2015 Q2	$2.76M	Buy	18,301 +81	+0.4%	+$11.6K	0.02%	827
2015 Q1	$2.46M	Buy	18,220 +715	+4%	+$88.6K	0.02%	824
2014 Q4	$2.11M	Buy	17,505 +204	+1%	+$23.5K	0.01%	955
2014 Q3	$1.96M	Buy	17,301 +393	+2%	+$46.6K	0.01%	955
2014 Q2	$2.02M	Buy	16,908 +122	+0.7%	+$14.9K	0.01%	999
2014 Q1	$2.15M	Buy	16,786 +319	+2%	+$40.9K	0.01%	951
2013 Q4	$2.04M	Buy	16,467 +123	+0.8%	+$15K	0.01%	972
2013 Q3	$1.92M	Buy	16,344 +34	+0.2%	+$4.01K	0.01%	954
2013 Q2	$1.83M	Buy	+16,310	New	+$1.91M	0.01%	930

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BIO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 845 shares — an estimated $292K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BIO in Q2 2013 and held it in 44 quarters. The position peaked at $4.43M in Q2 2017. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 845 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $292K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 44 quarters.
Metropolitan Life Insurance Company (MetLife)'s Bio-Rad Laboratories Class A position peaked at $4.43M in Q2 2017.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.